Enno Spillner - Evotec AG Insider

Evotec AG -- USA Stock  

USD 20.35  0.00  0.00%

CFO, Member of the Management Board

Mr. Enno Spillner was Chief Financial Officer and Member of the Management Board of Evotec AG since July 18, 2016. From April 2013 until June 2016 he served as Chairman of the Management Board, Chief Executive Officer and Chief Financial Officer of 4SC AG. He joined the 4SCs Management Board already in September 2005 as CFO. Before working for 4SC, Mr. Spillner was Head of Finance and Controlling at BioM AG, a German regional biotech venture fund, which he joined at the beginning of 1999. In this role he was, besides finance and controlling, responsible for managing investments in the equity portfolio and also held the position of interim Managing Director at two portfolio companies ACTIPAC Biosystems GmbH and Munich Innovative Biomaterials GmbH. In September 2001, he also assumed the position as Management Partner of BioM VC Fund. He began his career at MediaPlus Spezialagentur fr Media GmbH, Munich. Since 2014 he has also been Member of the Supervisory Board and Chairman of the Audit Committee at Nanobiotix, Paris
Age: 46  CFO Since 2016      
49 40 5 60 81 0  http://www.evotec.com
Spillner earned his Dipl.Kaufmann degree at Universitaet Bamberg.

Management Efficiency

The company has return on total asset (ROA) of 4.56 % which means that it generated profit of $4.56 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 11.13 % meaning that it generated $11.13 on every $100 dollars invested by stockholders.
The company has accumulated 213.13 M in total debt with debt to equity ratio (D/E) of 53.9 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Evotec AG has Current Ratio of 0.68 indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due.

Similar Executives

Entity Summary

Evotec AG provides drug discovery solutions to the pharmaceutical and biotechnology companies, academic institutions, and foundations and not-for-profit organizations worldwide. Evotec AG was founded in 1993 and is headquartered in Hamburg, Germany. Evotec AG is traded on OTC Market in USA.Evotec AG (EVOTF) is traded on OTC Market in USA. It is located in Manfred Eigen Campus and employs 1,238 people.

Did you try this?

Run Watchlist Optimization Now

Watchlist Optimization

Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Hide  View All  NextLaunch Watchlist Optimization
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Evotec AG to your portfolio

Top Management

Evotec AG Leadership Team
Werner Lanthaler, CEO
Claus Braestrup, Executive
Michael Shalmi, Executive, MBA
Mario Polywka, COO, Ph.D
Mary Tanner, Executive
Roland Oetker, Chairman
Andreas Pinkwart, Executive
Paul Herrling, Executive, Ph.D
Colin Bond, CFO, MBA
Cord Dohrmann, Executive
Iris LoewFriedrich, Executive, Ph.D
Bernd Hirsch, Executive
Enno Spillner, CFO
Elaine Sullivan, Executive
Wolfgang Plischke, Chairman, Ph.D

Stock Performance

Evotec AG Performance Indicators